v3.26.1
Segment and Geographic Information - Schedule of Segment Income of LivaNova’s Reportable Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Net revenue $ 390,587 $ 352,524 $ 752,845 $ 669,379
Cost of sales 116,917 113,536 235,426 214,137
Selling, general, and administrative 158,128 137,780 301,696 266,926
Research and development 53,662 47,185 112,357 85,064
Operating income 49,484 54,183 90,955 102,800
Operating Segments        
Segment Reporting [Line Items]        
Operating income 89,087 87,427 163,308 164,471
Operating Segments | Cardiopulmonary        
Segment Reporting [Line Items]        
Net revenue 221,576 199,272 430,231 375,592
Cost of sales 97,265 95,465 198,194 180,385
Selling, general, and administrative 66,465 56,012 126,314 109,971
Research and development 18,376 16,465 36,171 28,509
3T litigation provision 11,318 (77) 11,333 629
Operating income 28,152 31,407 58,219 56,098
Operating Segments | Neuromodulation        
Segment Reporting [Line Items]        
Net revenue 166,945 151,670 318,733 290,563
Cost of sales 14,455 14,769 28,676 28,155
Selling, general, and administrative 56,568 51,097 109,187 98,667
Research and development 34,987 29,784 75,781 55,368
3T litigation provision 0 0 0 0
Operating income $ 60,935 $ 56,020 $ 105,089 $ 108,373